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1. INTRODUCTION 
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1.1. POSTERIOR VITREOUS DETACHMENT 
The cell adhesion proteins laminin and fibronectin fix the posterior vitreous body to 
the internal limiting membrane (ILM) of the retina (1). Vitreous collagen fibers pass at the 
vitreous base directly through the ILM communicating with retinal collagen (2). Henrich et 
al. showed that this communication between retina and vitreous body varies at different 
locations. The attachment is stronger at the vitreous base, optic disc, fovea and along major 
retinal blood vessels (3). The detachment of vitreous body from the ILM is a common 
condition in the aging eye, most often resulting in complete vitreoretinal separation. 
With increasing age this physiological process of posterior vitreous detachment (PVD) 
increases as well. Focal perifoveal PVD occurs in half of 30-39 year-old subjects. In at least 
60% of the population complete detachment can be shown by the age-range of 80-90 (4-6). 
The first stage in the development of the full-blown synchisis senilis is an age-related vitreous 
gel liquefaction leading to the formation of fluid-filled cavities, which subsequently 
condensate (syneresis) (7). The result is a dehiscence in the cortical gel and/or posterior 
hyaloid membrane (8). The process of PVD can be divided into 5 stages, which can nicely be 
observed with the help of OCT. Stage 0 means that there is no dehiscence and no signs of 
detachment at all. First small areas of detachment occur most commonly in the perifovea, 
especially in the superior quadrants. These mark the onset of stage 1 PVD. In stage 2 these 
areas of detachment extend further into the perifovea, but attachment to the fovea itself and 
the optic nerve head persists. With detachment from the fovea, but still persistent attachment 
to the optic nerve head and the posterior surface of the eye one grades the OCT-finding as 
stage 3 PVD. And finally the complete detachment of the vitreous body from fovea, the optic 
nerve head, and the entire posterior eye surface is categorized as stage 4 PVD (Figure 1) (1). 
Patients often don’t experience any symptoms, but in up to 27% of cases 
complications may occur (9). Hence one can characterize PVD as either symptomless and 
physiologic or symptomatic and anomalous, disturbing a patient’s visual perception. The 
perception of floaters, few small spots becoming dense upon time, is termed myodaeopsia or 
muscae volitantes in Latin (10). They are especially prominent while looking at something 
bright and pale, e.g. a white wall or the clear blue sky. Photopsia, often described as a 
lightning-like arc induced by eye or head movement and prominent in dim conditions, is 
another common finding. And a third accompanying symptom is sometimes also blurred 
vision together with a reduction in visual acuity (VA) due to dispersed haemorrhage within 
the vitreous gel. An incomplete or anomalous dehiscence of central macula and optic nerve 
head may lead to a range of macular conditions. Spectral Domain Optical coherence 
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tomography (SD-OCT) comprises the method of choice for differentiation of these diseases of 
the vitreomacular interface (11, 12). 
 
 
 
Figure 1. Development of age-related PVD as seen by OCT – schematic and respective OCT-
finding. From: Initial Stages of Posterior Vitreous Detachment in Healthy Eyes of Older 
Persons Evaluated by Optical Coherence Tomography (1) 
 
 
1.2. CLASSIFICATION OF VITREOMACULAR INTERFACE DISEASE 
Vitreomacular traction (VMT) syndrome is a disturbance of the vitreo-retinal 
interface. Necessary for a diagnosis of VMTS are an incomplete posterior vitreous 
detachment (PVD), a strong attachment of the hyaloid to the macula as well as a resultant 
anteroposterior traction exerted by the synergetic vitreous pulling motion at sites adhering to 
the macula (13). Morphologic changes and functional effects can be the consequence (14). 
In 2013, the International Vitreomacular Traction Study (IVTS) Group developed an optical 
coherence tomography (OCT)-based anatomic classification system for diseases of the vitreo-
retinal interface (15). 
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Table 1. Classification of vitreomacular interface disease according to IVTS-Group. From: 
Duker et al. The International Vitreomacular Traction Study Group Classification of 
Vitreomacular Adhesion, Traction, and Macular Hole (15) 
 
 
1.2.1. Vitreomacular adhesion (VMA) 
Evidence of partial vitreous detachment in the perifoveal area on at least one OCT 
finding points towards two entities, namely VMA and VMT (16). Both VMA and VMT show 
the hyaloid attachment to the macula within a radius of at least 3mm from the fovea, as well 
as an angle between retinal surface and posterior hyaloid, but unlike in VMT, there is no 
traction and therefore no change in the foveal contour nor any other retinal morphological 
changes (15). In fact the condition is benign, patients are asymptomatic and a watchful 
waiting approach is indicated (17). 
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1.2.2. Vitreomacular Traction (VMT)/Vitreomacular Traction Syndrome (VMTS) 
Historically, Irvine described the “vitreous tug syndrome” after cataract surgery in 
1953. Following cataract extraction vitreous incarceration at the corneal wound sites would 
occur leading to cystoid macular edema from vitreomacular traction (18). A few years later in 
1967, Jaffe described a distinct “vitreoretinal traction syndrome” in 14 phakic patients (19). 
Reese et al. then studied the changes in VMT occurring at the macula. They incorporated 
Irvine’s and Jaffe’s descriptions into a spectrum of disease, with aphakia being a risk factor 
possibly leading to more severe changes through extra traction (14). Finally, Reese et al. 
provided histopathologic proof in 1970, confirming “vitreomacular traction syndrome” (13). 
 
 
 
 
Figure 2. A section through the fovea shows the partially detached posterior hyaloid with 
persistent attachment to the internal limiting membrane in the foveal region; A: Centre; 
detached hyaloid membrane (a), still attached to the internal limiting membrane (b & b’) at 
the macula. From: Reese AB, Jones IS, Cooper WC. Vitreomacular traction syndrome 
confirmed histologically (13) 
 
The IVTS Group defines the presence of retinal changes on OCT with evident 
perifoveal PVD leading to a distorted foveal surface contour as Vitreomacular Traction 
(VMT) (15). Traction occurs due to the persistent attachment of the posterior hyaloid to the 
macula and blood vessels on the posterior surface (20). VMT is, according to the IVTS 
Group, further sub-classified based on the measured adhesion length of the vitreous cortex to 
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the macula into focal and broad VMT (15). Focal VMT hereby, means an adhesion length of 
no more than 1500µm, whereas broad VMT is an adhesion of more than 1500µm (Table 1). 
The IVTS Group further differentiates isolated VMT, when no other macular comorbidity is 
found, and concurrent VMT, in which other conditions of the macula, e.g. diabetic macular 
edema, occur together with VMT (15, 20). 
 
1.3. DIAGNOSIS OF VMT 
The Diagnosis of vitreoretinal interface diseases comprises a broad palette of 
diagnostic methods. Ophthalmoscopy, biomicroscopy, visual function tests (e.g. Amsler test, 
Watzke-Allen test, laser beam test, microperimetry), ultrasonography in both A and B mode 
all have their role in the diagnostic workup (17). However most crucial instruments today are 
modern imaging technologies, such as the very sensitive spectral domain OCT with confocal 
scanning laser ophthalmoscope (SD-OCT/SLO) (21). Of course also older generations of 
OCT can be used for a proper diagnosis (16). 
 
1.3.1. Symptoms 
Symptoms of VMT comprise mainly a decreased reading vision, but less 
metamorphosia than in patients with macular puckers (MP) (9, 22). Sometimes patients 
describe micropsia and photopsia (9, 23). Metamorphopsia is a term for the distortion of 
perceived images, whereas micropsia stands for the decrease in the image size, usually due to 
the spreading apart of foveal cones. Traction on the retina from the detaching vitreous causes 
photopsia meaning the perception of flashing lights (10, 17). 
 
1.3.2. Signs 
Binocular stereoscopic biomicroscopy is often challenging, especially in cases with a 
broad area of attachment (>1500µm). The diagnosis can often only be presumed when 
findings of retinal surface thickening, wrinkling and distortion, cystoid macular edema, foveal 
pseudocyst, macular schisis or detachment, and capillary leakage are present. A whitish band 
or reflex resembling the limits of the attached vitreous may be seen. These changes may be 
very subtle and the diagnosis can often only be presumed. In fact key to diagnosis are OCT 
results. 
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Figure 3. Fundus photograph in a patient with vitreomacular traction syndrome showing a 
whitish glistening translucent outline of vitreomacular attachment sites (arrowheads) 
involving the macula and the peripapillary retina. (c) 2013 American Academy of 
Ophthalmology. Available from: 
https://eyewiki.aao.org/Vitreomacular_Traction_Syndrome#cite_note-ref11-11. 
 
1.3.3. OCT 
Due to the development and use of high-resolution optical coherence tomography 
(Spectral-Domain-OCT, SD-OCT) a causal connection between persistent vitreomacular 
adhesions and the development of diverse macular diseases could be established (24). When 
there is a clinical suspicion of vitreomacular traction syndrome, OCT has been shown to be 
very helpful not only in establishing a diagnosis, but also in the follow-up of patients, who 
came to attention (25, 26). Reasonably the IVTS-group based their definitions on OCT-
findings. 
As already shown and described above, findings show perifoveal PVD with macular 
attachment of cortex within a foveal radius of 3mm. Distortion of foveal surface, intraretinal 
changes or foveal elevation above RPE may be present. Focal VMT involves an area of 
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attachment of <1500µm diameter, and broad VMT an area of >1500µm diameter (8, 12, 15). 
Concurrent VMT is associated with other macular disease, eg. AMD, DR, etc.. In isolated 
VMT there is no other macular disease present (15, 16). 
 
 
 
Figure 3. Optical coherence tomography (OCT) scans showing vitreomacular traction (VMT) 
according to the IVTS Classification System for Vitreomacular Adhesion, Traction, and 
Macular Hole. (D) Focal VMT; (E) Focal VMT with intrafoveal pseudocyst; (F) Broad VMT 
From: Duker et al. The International Vitreomacular Traction Study Group Classification of 
Vitreomacular Adhesion, Traction, and Macular Hole (15) 
 
1.3.4. Differential Diagnosis 
Similar clinical features can be observed in early full thickness macular holes, 
pseudophakic cystoid macular edema (CME), but also other reasons for CME, such as 
diabetic macular edema or exudative age-related macular degeneration (AMD) have to be 
considered and excluded if appropriate (27). The fundoscopic appearance (Figure 3) can 
easily be mistaken for an ERM. OCT brings clarity if one is unsure based on other clinical 
features and examinations. 
 
1.4. MANAGEMENT OF VMT 
Currently observation and watchful-waiting or surgery are the usual approach in the 
management of vitreomacular pathology (28). Depending on clinical presentation and severity 
of disease there are several treatment options. As resolution can occur spontaneously an 
observative and watchful waiting approach can be attempted in asymptomatic patients. 
However if VMT persists and symptoms are significant or bothersome treatment should be 
provided as foveal damage may occur (23). In fact for an appropriate patient management a 
strict differentiation between «symptomatic» VMT and «asymptomatic» VMT is necessary 
(see above). 
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1.4.1. Observation 
Some of the patients, especially milder cases, will experience spontaneous resolution 
of their VMT. However literature reveals a varying occurrence of this phenomenon (29-31). 
Nonetheless a watchful-waiting approach is advisable for patients with VMA and many 
patients with VMT (17). Even when a surgical approach is considered an observation period 
of 2-3 months could be beneficial (26). Good prognostic factors for a successful spontaneous 
resolution rate seem to be younger age, focal VMT, absence of ERM and the presence of 
subretinal fluid (30). 
 
1.4.2. Pharmacological vitreolysis 
The gold standard in the choice of an intervarntional approach used to be and is still a 
pars-plana-vitrectomy (PPV) (28, 32). Yet, every surgical intervention brings about many 
perioperational risks and high costs (33, 34). Despite PPV's high success rate, the risks of 
surgery lead to the search for non-surgical treatment options for VMT. One such option was 
the development of pharmacological vitreolysis. In October 2012 the FDA approved 
Ocriplasmin (JetreaTM, ThromboGenics, Inc. Iselin, NJ) as a non-surgical, pharmacological 
agent for the treatment of VMT symptoms (35). In Croatia and Europe it is available since 
March 2013 (36). Again careful patient selection is indispensable and not all patients will 
benefit from a pharmacological treatment of their disease (37). The potential side-effects of 
Ocriplasmin include vitreous floaters, zonular instability and transient vision loss (38). 
Although primary study outcomes on the efficacy of pharmacological vitreolysis have shown 
statistically significant results compared to placebo, comparing these results to surgical 
interventions the view of high associated costs for the drug will yield disappointing and 
weaker clinical utility (39), especially in lower income countries. Studies comparing cost 
utility of enzymatic vitreolysis and pars-plana-vitrectomy show that ocriplasmin is still less 
cost-efficient compared to vitrectomy surgery in primary management of VMT (40). In fact 
there still is a need for searching cheaper and less invasive treatment options. 
 
1.4.3. Pars-plana-vitrectomy (PPV) 
Pars-plana-vitrectomy with peeling of all adhering areas and, if present, all epiretinal 
membranes (ERM) is an efficient and economical method for managing VMT (28, 40). Some 
authors claim that a simultaneous removal of the Internal Limiting Membrane (ILM) is linked 
to a reduction in the (re-) occurrence of ERMs (41). Indications of vitrectomy are 
symptomatic progressions of VMT, characterized by a decrease in visual acuity, 
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metamorphopsia or double vision (20, 28). Many authors report promising outcomes. An 
average improvement of visual acuity by two lines, reduction of central macular thickness and 
improvement of even resolution of metamorphosia can be expected (23, 33, 42). Again 
patients with focal VMT had better postoperative improvement than patients with broad VMT 
(23). 
 
1.4.4. Pneumovitreolysis 
Previous studies have shown that intravitreal injections of gas bubbles (pneumatic 
vitreolysis) can lead to the closure of a macular opening by inducing PVD (43). Additional 
studies have shown that intravitreal gas bubbles alone can induce PVD in patients with non-
proliferative diabetic retinopathy (44) and diabetic macular edema (45). Kim et al. have 
shown that intravitreal gas bubbles in combination with anti-vascular endothelial growth 
factor drug can induce the resolution of VMT in patients with wet macular degeneration in 
4/4 (100%) eyes (46). Nonetheless, there is a lack of literature about the specific treatment of 
an isolated VMT only with intravitreal gas injection. Rodrigues et al. have shown that one 
intravitreal injection of the gas perfluoropropane (C3F8) can cause the resolution of VMT in 
5/7 (70%) of eyes with isolated VMT and in 3/6 (50%) in eyes with diabetic macular edema 
(47). Pneumatic vitreolysis carries the potential of a safe, cheap and effective therapy, which 
could represent an asset in the management of patients with symptomatic vitreomacular 
traction. 
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2. OBJECTIVES 
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AIM: 
The purpose of our study is to estimate the effectiveness and safety of a single sulfur 
hexafluoride (SF6) intravitreal injection for patients with vitreomacular traction. 
 
HYPOTHESIS: 
The hypothesis is that the single sulfur hexafluoride intravitreal injection resolves 
vitreomacular traction in a significant number of patients with no side effects. 
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3. MATERIALS AND METHODS 
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3.1. ETHICAL APPROVAL & PROTOCOL REGISTRATION 
The consent for conduction of this research was obtained from the Ethical Committee 
of the University Hospital of Split. In accordance with the Medical Code of Ethics, the data 
obtained in this research was and will be kept and handled strictly confidential. All reports 
generated on the basis of this study will utilize the data of a sample of patients with a 
diagnosis of vitreomacular traction fulfilling the eligibility criteria prior to intervention 
(section 3.2. Patient Population). The purpose of the examinations, procedures, possible 
advantages, disadvantages and possible side effects of the intervention were explained to all 
participants, possible questions were answered and a signed informed consent was obtained. 
The study protocol was registered at clinicaltrials.gov (NCT03945695). 
 
 
3.2. PATIENT POPULATION 
Patients were selected from the pool of patients coming to the outpatient unit of the 
Department of Ophthalmology, University Hospital of Split, according to the criteria of 
inclusion and exclusion as stated below. After obtaining informed consent all patients were 
assigned into the intervention group and received treatment according to a predefined 
procedural protocol. Neither participants nor researchers were blinded during the whole 
course of the study. 
 
3.2.1. Inclusion criteria 
Participants needed to be 18 years or older and able to give written informed consent 
to the procedure. A diagnosis of symptomatic VMT based on clinical and OCT-findings, as 
described above, was necessary for inclusion. 
 
3.2.2. Exclusion criteria 
Patients presenting with any form of retinal tear, macular degeneration, vascular 
occlusion of the retina, aphakia, high myopia (> -8 diopters), uncontrolled glaucoma, vitreous 
opacities, retinal ablation, vitrectomy were not eligible for inclusion. 
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3.3. OUTCOME MEASURES 
The primary outcome measure was VMT resolution as determined by OCT. 
Secondary outcomes were improvement of best-corrected visual acuity (BCVA), foveal 
outline focusing on vitreomacular adhesion presence and length, central foveal thickness 
(CFT) one week, 2 weeks and one month post intervention in comparison to preoperative 
findings. Furthermore, other secondary outcomes were maximum central foveal thickness at 
the one-month post interventional follow-up visit, time needed for the resolution of VMT, 
occurrence of any side-effects, such as retinal tears, retinal detachment and treatment failure 
rate. 
 
 
3.4. SURGICAL PROCEDURE 
Patients were selected according to the inclusion criteria mentioned above. After 
appropriate anesthesia with topical lidocain and antiseptic preparations of the surgical field 
with 5% povidone iodine, a paracentesis of the anterior chamber was performed in order to 
induce hypotony and to prevent hypertony after the injection of the gas buble. Subsequently 
an intravitreal injection of 0.2 to 0.3 ml of undiluted filtered sulfur hexafluoride gas (SF6) 
into the treated eye via pars plana at 3,5 mm from the limbus. Intraocular pressure of the 
examined eye was controlled before the intervention and kept at an appropriate level after 
paracentesis by manual application of pressure over the cornea with the rubber end of an 
insulin syringe plunger. All patients were required to avoid the supine position and had to lie 
on one side or the abdomen during sleep until complete resorption of the intraocular gas. 
During this period they were additionally asked to bend over several times during the day at 
least up to an angle of 90º or as much as possible, resembling the movement of a bird 
drinking water. (Hence the name «drinking-bird-technique».) 
 
 
3.5. OPHTHALMOLOGIC EXAMINATION AND DATA COLLECTION 
One of the investigators carried out regular control examinations at one week after the 
procedure, and thereafter at weeks 2 and 4. During each control examination best-corrected 
visual acuity, reported on a decimal scale, and intraocular pressure, in mmHg, were measured. 
Moreover biomicroscopy, indirect ophthalmoscopy, and macular OCT (Cirrus OCT 5000 
HD, Zeiss, Jena, Germany) of the treated eye were performed. The following data were also 
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recorded by the same investigator: patient demographics (age, gender, affected eye, 
comorbidities), period of time between the intravitreal injection of gas to the separation of the 
posterior hyaloid membrane. Any adverse events that have occurred after gas injection, 
including eye complications (eg. retinal tear or ablation, infections, increase in intraocular 
pressure, uveitis, bleeding and damage to the optic nerve), and systemic complications, were 
also recorded. 
 
 
3.6. STATISTICAL ANALYSIS 
Descriptive statistics was used for patient demographic data and baseline 
characteristics. The small sample size made us report continuous variables as medians ± 
interquartile range (IQR), minimum and maximum. Frequencies and proportions, as well as 
mean times to resolution were described for categorical variables. 
Statistical analysis was performed using Statistical Package for Social Sciences 
(SPSS) Statistics, version 25.0 (IBM SPSS Statistics, Armonk, NY, USA). 
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4. RESULTS 
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A total number of eleven eyes from nine patients were included in our pilot study. 
Both gender and sides were equally distributed, with six out of eleven eyes being the right 
eye, and five out of eleven eyes being the left eye of the patient. In two patients both left and 
right eyes were affected by VMT and treated with a gap of three weeks between interventions. 
Interestingly treatment was for both eyes similarly effective in both of the patients, although 
one of them was affected by broad VMT in one eye and focal VMT in the second eye. 
Out of the nine patients five were female and four were male accounting for five out 
of eleven male eyes and six out of eleven female eyes. Included patients were on average 72 
years old, with the youngest being 56 years old and the oldest 84. Majority of patients were 
affected by a focal VMT, namely in eight out of eleven cases (72.7 %), broad VMT was 
present in the remaining three eyes (27.3 %). Patient characteristics are given in Table 2. 
 
Table 2. Patient Characteristics: Gender; Eye affected by VMTS and treated by 
pneumovitreolysis. 
 Frequency [in n/N 
(%)] 
Resolution [in n/N 
(% from own group; 
% from total)] 
Mean time to 
resolution [in weeks 
after intervention] 
Total 11/11 (100) 2/11 (18.2) 1.5 
Male 5/11 (45.5) 1/5 (20; 9) 2 
Female 6/11 (54.5) 1/6 (16.7; 9.1) 1 
Right eye 6/11 (54.5) 1/6 (16.7; 9.1) 1.5 
Left eye 5/11 (45.5) 1/5 (20; 9) 1 
Focal 8/11 (72.7) 1/8 (12.5; 9.1) 1 
Broad 3/11 (27.3) 1/3 (33.3; 9) 2 
Categorization of VMT (focal=<1500µm or broad=>1500µm) 
In one out of the eleven included eyes resolution occurred on average after 1.5 weeks. 
In one eye with focal VMT no adhesion was visible on the first control visit, whereas 
resolution in the eye affected by broad VMT, resolution was only detectable on the second 
control visit. In a further eye, affected by focal adhesion, macular adhesion length decreased 
significantly from 267nm to 30nm at one-month post intervention. Unfortunately resolution 
wasn’t achieved. Remaining eyes didn’t show a significant decrease despite intravitreal gas 
injection. In fact after the one-month follow-up period a resolution was achieved in 2 out of 
11 eyes (18.2%) (Figure 4 & Table 2). Nonetheless median adhesion length decreased from 
620µm before gas injection to a median adhesion length of 599 after injection in eyes without 
resolution (Table 6). 
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Figure 4. Resolution of VMT at the 3rd control visit (1 month after gas injection). 
 
Improvement in visual acuity was detectable after resolution in the eye with focal 
VMT, but also in the eye with adhesion decrease. Unfortunately, there was no improvement 
in VA in the eye with broad VMT during our one-month follow-up period. The largest 
improvement was reported for one eye with an increase in VA by 0,4 (from previously 0,2 up 
to 0,6 at 1 month post intervention). Unfortunately median improvement from 0.4 before 
intervention to 0.5 after intervention in eyes with resolution was less impressive (Table 3 and 
Table 4). Since the patients didn’t have any other symptoms characteristic for sVMT, the 
researchers cannot report any improvement or worsening. There was no increase in IOP due 
to the injection of intraocular gas. The investigators rather measured a slight decrease in IOP 
at the first control visit, which normalized until the end of the one-month follow-up period. 
The median IOP didn’t differ significantly in both groups of eyes with and without resolution 
(Table 5). 
None of the nine patients reported any side effects and they tolerated the injection 
quite well. Table 3 offers an overview of the preoperative patient characteristics. Mean age of 
included patients was 69 years. A high variation in preoperative best-corrected visual acuity 
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could be noted. Based on adhesion length one can see that both focal and broad VMTs were 
present in our sample (Table 3). 
Central foveal thickness was slightly lower in eyes achieving resolution than in eyes 
without resolution. This difference however was evident even before application of 
intravitreal gas. Interestingly though a slightly faster decrease in CFT could be noted in eyes 
achieving resolution (Table 7). 
Table 3. Descriptive Statistics for continuous variables – pre-interventional 
 N Median Interquartile Range Minimum Maximum 
Age at time of 
operation 
11 69 66-82 56 84 
Preoperative 
Visual acuity 
11 0.4 0.2-0.7 0.08 0.7 
Preoperative 
Intraocular 
Pressure 
(IOP) 
11 16 14-18 13 20 
Preoperative 
Adhesion 
length as seen 
on OCT 
11 620 326-1620 87 2271 
Preoperative 
CFT as seen 
on OCT 
8 280.5 
270.25-
298.25 
263 337 
 
 
 
Table 4. Visual acuity – post-interventional 
Resolutio
n occured 
during 
follow-up 
Statistical 
Measure 
Visual Acuity on 
1st control 
examination (1 
week postop) 
Visual Acuity on 
2nd control 
examination (2 
weeks postop) 
Visual Acuity 
on 3rd control 
examination (1 
month postop) 
Median 0.4 0.4 0.5 
Interquartile 
Range 
0.4-0.4 0.4-0.4 0.4-0.6 
Minimum 0.4 0.4 0.4 
Yes (N=2) 
Maximum 0.4 0.4 0.6 
Median 0.3 0.5 0.5 
Interquartile 
Range 
0.2-0.5 0.3-0.6 0.3-0.6 
Minimum 0.04 0.02 0.02 
No (N=9) 
Maximum 0.7 1.00 0.7 
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Table 6. Adhesion length – post-interventional 
Resolutio
n occured 
during 
follow-up 
Statistical 
Measure 
Adhesion length 
on 1st control 
examination (1 
week postop) as 
seen on OCT 
Adhesion length 
on 2nd control 
examination (2 
weeks postop) as 
seen on OCT 
Adhesion 
length on 3rd 
control 
examination (1 
month postop) 
as seen on OCT 
Median 865.0 0.0 0.0 
Interquartile 
Range 
0-1730 0-0 0-0 
Minimum 0 0 0 
Yes (N=2) 
Maximum 1730 0 0 
Median 601.0 602.0 599.0 
Interquartile 
Range 
385-1080 356-1100 356-1101 
Minimum 45 45 30 
No (N=9) 
Maximum 2314 2240 2239 
 
 
 
 
 
 
Table 5. Intraocular pressure – post-interventional 
Resolutio
n occured 
during 
follow-up 
Statistical 
Measure 
IOP on 1st 
control 
examination (1 
week postop) 
IOP on 2nd 
control 
examination (2 
weeks postop) 
IOP on 3rd 
control 
examination (1 
month postop) 
Median 15.0 15.0 15.0 
Interquartile 
Range 
13-17 15-15 15-15 
Minimum 13 15 15 
Yes (N=2) 
Maximum 17 15 15 
Median 13.0 13.0 13.0 
Interquartile 
Range 
12-18 12-18 12-18 
Minimum 12 11 12 
No (N=9) 
Maximum 18 19 21 
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Table 7. Central Foveal Thickness (CFT) – post-interventional 
Resolutio
n occured 
during 
follow-up 
Statistical 
Measure 
CFT on 1st 
control 
examination (1 
week postop) as 
seen on OCT 
CFT on 2nd 
control 
examination (2 
weeks postop) as 
seen on OCT 
CFT on 3rd 
control 
examination (1 
month postop) 
as seen on OCT 
Median 266.0 264.0 260.0 
Interquartile 
Range 
258-274 263-265 253-267 
Minimum 258 263 253 
Yes (N=2) 
Maximum 274 265 267 
Median 333.0 332.0 330.0 
Interquartile 
Range 
308.5-389 276.5-426.5 288-388.5 
Minimum 260 248 262 
No (N=7) 
Maximum 446 648 621 
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5. DISCUSSION 
24	
Our pilot study assessed the efficacy of an intravitreal injection of sulfuhexafluoride 
(SF6) gas for the management of patients with symptomatic vitreomacular traction. Treatment 
was successful in about a fifth of included eyes after a one-month follow-up period. The 
success rate of exactly 18.2% was slightly lower than expected. 
Earlier reports described higher resolution rates with a similar methodology. Chan et 
al. first described the procedure in 1995 icluding 18 patients in his study (48). No information 
on adhesion length was provided. Chan et al. used a different expansile gas, namely 
perfluoropropane (C3F8) and achieved VMT release in 96% of cases. In a later study Jorge et 
al. achieved an impressive 100% VMT-release in 6 patients with stage II macular holes (49). 
Again adhesion lenghth wasn't reported. Rodrigues et al. reported a resolution of 40% in 15 
eyes affected by focal VMT at a one-month post intravitreal gas injection with expansile 
perfluoropropane (C3F8) (47). 
In 2017 Steinle et al. and Chan et al. independently conducted larger retrospective 
studies looking at 30 eyes affected by focal VMT and 50 eyes, respectively, with a 73% and 
86% VMT-release after one month follow-up (50, 51). 
In view of these previous reports, our results are in favor of the observation that the 
utilization of a long-acting gas generally yields better resolution rates than a short-acting 
one.(52) This observation was very well elaborated by Čokl and Petrovič, who compared 29 
eyes receiving C3F8 with 28 eyes receiving an injection of SF6. Resolution rate in the C3F8 
group was 62%, whereas as resolution rate of 21.4% was achieved in the SF6 group (53). 
A reason for these results favoring C3F8 could be the prolonged resorption time of 
C3F8 compared to SF6, giving it more time to act and have an effect (54). The ability to 
expand and even quadruple prolongs time of action even more (51). In fact, what matters 
more is resorption time rather than bubble size (55). 
Still the possibility of good results after SF6 injection cannot be completely ruled out. 
Ochoa-Contreras et al. injected 0.5 mL of SF6 in 12 eyes of patients with nonproliferative 
diabetic retinopathy and achieved an impressive resolution rate of 100% (44). 
Later also Buzzacco et al. reported very successful results for sulfurhexafluoride 
injections. In a case series in 2017 they achieved a resolution in 87% of their included 
patients. Unfortunately with only six patients their sample size was even smaller than in our 
study, also no clear inclusion and exclusion criteria were applied, which made the patient 
population quite heterogeneous (56). 
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Day et al. conducted another successful study quite similar to ours. They included 
eight eyes affected by focal and one eye affected by broad VMT. A resolution in 55.6% of 
cases was achieved (57). 
And finally a bigger study was conducted by Javed et al. in 2018, which was most 
comparable to our own. They included a total of 21 patients and reached a significant 
resolution of 42.9% after a one-month follow-up period. Unfortunately there was no mention 
of adhesion length in the sample population (55). These remarkable results show that 
pneumatic vitreolysis using sulfurhexafluoride can be similarly effective in selected patients 
with focal VMT. Our results coincide with these observations. 
Furthermore a shorter resorption time of SF6 means that patients can return earlier to 
normal activities and travel, a point to consider in people working in environments with 
changing air pressures. Also the additional strain on a non-detaching VMT is reduced, 
minimizing the risk of unwanted side effects, such as retinal tears. 
In view of the low cost, convenience and easy availability of applying intravitreal gas 
in patients with symptomatic VMT, the investigators believe that it has the potential of 
becoming a good initial management in part of the affected patient population. Especially in 
countries with a lower health care budget and with less available surgical expertise, 
pneumovitreolysis serves as a worthwhile initial alternative to the much more costly 
ocriplasmin treatment and the more invasive and more demanding PPV. 
For the same reasons an implementation in standard procedure of care, possibly 
second-line after watchful-waiting, could be worthwhile even in higher income regions. Not 
only for economical and organizational reasons, but also to spare patients, in whom it is 
successful, possible side-effects of enzymatic vitreolysis and the discomfort of a substantial 
ophthalmic surgery. 
Due to the fact that this study served as an evaluation of feasibility of the proposed 
treatment and in order to get investigators familiarized with the treatment implementation a 
small sample size was used. The investigators therefore cannot make large-scale inferences 
about treatment effect. Furthermore, patients were followed rather shortly and it is possible 
that there are changes, perhaps even additional resolutions, after a longer post-interventional 
period. Another drawback was the fact that patients were performing their exercises 
scheduled at home and not in a more controlled environment. In fact, although the researchers 
made sure that patients understood how to perform the “drinking-bird”-movement and they 
were asked and reminded at every follow-up visit, actual compliance cannot be assured. 
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A benefit of conducting studies in Dalmatia is that one can easily obtain a very 
homogenous treatment naïve sample population. This geographical and cultural peculiarity is 
an advantage and strength of this study. 
Another consideration originated in the observation that majority of resolutions were 
noted at the first post-interventional check-up. This very short time to resolution raised the 
question if mere mechanical manipulation alone was enough to cause the detachment of the 
adherent vitreous. In future trials it would be interesting to have a treatment-arm with only 
sham injections, to test if the effect of manipulation alone is enough to induce resolution and 
how much of a benefit the intravitreal gas injection brings to the procedure success rate. Such 
a study could furthermore compare the added effectiveness of different gases. 
As already noted above future studies should implement bigger sample sizes of at least 
44 patients in order to yield sufficiently powered results. 
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6. CONCLUSIONS 
28	
Pneumovitreolysis with SF6 seems to be a safe, economical and effective minimally 
invasive first-line approach in the management of symptomatic vitreomacular traction. A 
consideration of including it into standard management guidelines, especially for cases of 
focal sVMT is worthwhile. Of course, further large-scale studies are necessary to confirm 
these preliminary findings. Furthermore, appropriate reporting guidelines for studies 
evaluating treatment of VMT should be designed in the interest of better comparability. 
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8. SUMMARY 
36	
Objectives: The aim of this study was to prove that pneumatic vitreolysis using the drinking 
bird technique is a safe and effective method for treatment of vitreomacular tractions. 
 
Materials and methods: Eleven patients who came to Department of Ophthalmology, 
University Hospital of Split, with OCT confirmed vitreomacular traction. Patients were 
treated with pneumatic vitreolysis using sulfur hexafluoride gas, after that they would do the 
“drinking bird” technique for the next two weeks. Patients were followed-up for 1 month. 
 
Results: Eleven eyes of nine patients affected by symptomatic vitreomacular traction (VMT) 
were included in this pilot study. Three out of eleven patients had broad (≥1500µm) VMT 
(N=3/11); Eight out of eleven patients had focal (≤1500µm) VMT (N=8/11). One week after 
the procedure, resolution of VMT had occurred in one out of eleven patients (N=1/11). Two 
weeks after treatment resolution had occurred in two out of eleven patients (N=2/11). 
Resolution had occurred in 12.5 percent of patients (N=1/8) with focal and thirty-three 
percent of patients with broad VMT (N=1/3). Eyes with focal VMT had a shorter time to 
resolution (mean time to resolution 1 week) than the eye with broad VMT (mean time to 
resolution 2 weeks). The improvement of the best-corrected visual acuity occurred in two out 
of three patients with traction resolution. Visual acuity improved in all eyes with achieved 
resolution from a mean pre-interventional VA of 0,4 on decimal scale to 0,5 post-
intervention. In none of the patients did intraocular pressure go beyond normal limits. In eyes 
without resolution macular adhesion length didn’t significantly decrease despite intravitreal 
gas injection. No complications following the procedure were recorded. 
 
Conclusions: Pneumatic vitreolysis using the “drinking bird” technique is a safe and effective 
alternative for the treatment of vitreomacular traction. 
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9. CROATIAN SUMMARY 
38	
Naslov: Pneumatska vitreoliza uz pomoć “drinking bird” tehnike u liječenju vitreomakularnih 
trakcija 
 
Ciljevi: Cilj ovog istraživanja je ispitati sigurnost i učinkovitost pneumatske vitreolize uz 
pomoć “drinking bird” tehnike u liječenju vitreomakularnih trakcija. 
 
Bolesnici i metode: Jedanaest bolesnika koji su došli u Kliniku za očne bolesti, KBC Split, s 
potvrđenom dijagnozom vitreomakularne trakcije. Bolesnici su bili podvrgnuti pneumatskoj 
vitreolizi s plinom sumporovim heksafloridom te su nakon zahvata iduća dva tjedna izvodili 
povremene nakolone gornjeg dijela tijela prema naprijed. Bolesnici su bili praćeni kroz 
mjesec dana. 
 
Rezultati: Tri bolesnika su imali široku vitreomakularnu trakciju, a osam bolesnika su imali 
usku vitreomakularnu trakciju. Na prvoj kontroli, tjedan dana nakon zahvata, rezolucija 
vitreomakularne trakcije nastupila je u jednom od ukupno jedanaest bolesniku (N=1/11). 
Nakon dva tjedna dva bolesnika imali su rezoluciju vitreomakularne trakcije. Rezolucija je 
nastupila u trinaest posto bolesnika s uskom i trideset tri posto sa širokom vitreomakularnom 
trakcijom. Do poboljšanja najbolje korigirane vidne oštrine došlo je u pedeset posto bolesnika 
u kojih je nastupila rezolucija trakcije. Niti jedan bolesnik nije imao postoperativno poviđenje 
intraokularnog tlaka. Nikakve komplikacije nakon zahvata nisu bile zabilježene. 
 
Zaključci: Pneumatska vitreoliza uz pomoć “drinking bird” tehnike je sigurna i valjana 
alternativa za liječenje vitreomakularnih trakcija. 
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